1. Scientific Advances and New Frontiers in Mesothelioma Therapeutics
- Author
-
Mutti, Luciano, Peikert, Tobias, Robinson, Bruce WS, Scherpereel, Arnaud, Tsao, Anne S, de Perrot, Marc, Woodard, Gavitt A, Jablons, David M, Wiens, Jacinta, Hirsch, Fred R, Yang, Haining, Carbone, Michele, Thomas, Anish, and Hassan, Raffit
- Subjects
Biomedical and Clinical Sciences ,Oncology and Carcinogenesis ,Cancer ,Lung Cancer ,Prevention ,Clinical Research ,Rare Diseases ,Lung ,Clinical Trials and Supportive Activities ,Humans ,Lung Neoplasms ,Mesothelioma ,Mesothelioma ,Malignant ,Malignant pleural mesothelioma ,Oncology therapeutics ,Biomarkers ,Immunotherapy ,Chemotherapy ,Cardiorespiratory Medicine and Haematology ,Clinical Sciences ,Oncology & Carcinogenesis ,Clinical sciences ,Oncology and carcinogenesis - Abstract
Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer that arises from the mesothelial surface of the pleural and peritoneal cavities, the pericardium, and rarely, the tunica vaginalis. The incidence of MPM is expected to increase worldwide in the next two decades. However, even with the use of multimodality treatment, MPM remains challenging to treat, with a 5-year survival rate of less than 5%. The International Association for the Study of Lung Cancer has gathered experts in different areas of mesothelioma research and management to summarize the most significant scientific advances and new frontiers related to mesothelioma therapeutics.
- Published
- 2018